Xuebin Liao

Xuebin Liao

Auto-generated profile, based on publicly available information

Xuebin Liao

School of Pharmaceutical Sciences, State Key Laboratory of Molecular Oncology, Tsinghua-Peking Center for Life Science, Tsinghua University, Beijing 100084, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
XZXu Zhang
Xu Zhang
BLBo Lei
Bo Lei
YYYuan Yuan
Yuan Yuan
LZLi Zhang
Li Zhang
LHLu Hu
Lu Hu
HQHai Qi
Hai Qi

1 October 2020 in Cancer Cell
Verified
Journal Article
Closed access
JSJingwen Si
Jingwen Si
XSXiangjun Shi
Xiangjun Shi
SSShuhao Sun
Shuhao Sun
BZBin Zou
Bin Zou
YLYaopeng Li
Yaopeng Li
XLXuebin Liao
Xuebin Liao

8 January 2016 in Organic Letters
Verified
Journal Article
Closed access
WJWenzhi Ji
Wenzhi Ji
LYLicheng Yao
Licheng Yao
XLXuebin Liao
Xuebin Liao

22 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
HWHaiyan Wang
Haiyan Wang
SLShasha Li
Shasha Li
QWQianyu Wang
Qianyu Wang
ZJZhengshuo Jin
Zhengshuo Jin
WSWei Shao
Wei Shao
DWDong Wang
Dong Wang
Combination immunotherapy is promising to overcome the limited objective response rates of immune checkpoint blockade (ICB) therapy. Here, a tumor immunological phenotype (TIP) gene signature and high-throughput sequencing–based high-throughput screening (HTS2) were combined to identify combination immunotherapy compounds. We firstly defined a TIP gene signature distinguishing “cold” tumors from “hot” tumors. After screening thousands of compounds, we identified that aurora kinase inhibitors (AKIs) could reprogram the expression pattern of TIP genes in triple-negative breast cancer (TNBC) cells. AKIs treatments up-regulate expression of chemokine genes CXCL10 and CXCL11 through inhibiting aurora kinase A (AURKA)–signal transducer and activator of transcription 3 (STAT3) signaling pathway, which promotes effective T cells infiltrating into tumor microenvironment and improves anti-programmed cell death 1 (PD-1) efficacy in preclinical models. Our study established a novel strategy to discover combination immunotherapy compounds and suggested the therapeutic potential of combining AKIs with ICB for the treatment of TNBC.

20 December 2019 in ACS Catalysis
Verified
Journal Article
Closed access
HCHui Chen
Hui Chen
SSShuhao Sun
Shuhao Sun
YLYahu A. Liu
Yahu A. Liu
XLXuebin Liao
Xuebin Liao

6 July 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
LHLu Hu
Lu Hu
XLXin Liu
Xin Liu
XLXuebin Liao
Xuebin Liao